Clinical Oncology
Volume 19, Issue 8 , Pages 572-576 , October 2007

Experience of the Use of Trabectedin (ET-743, Yondelis™) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre

  • R. Roylance

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK
    • Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • B. Seddon

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK
    • Corresponding Author InformationAuthor for correspondence: B. Seddon, The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK.
    • ,
  • A. McTiernan

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK
    • ,
  • K. Sykes

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK
    • ,
  • S. Daniels

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK
    • ,
  • J. Whelan

      Affiliations

    • The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London NW1 2PG, UK

Received 6 November 2006 ,Revised 8 May 2007 ,Accepted 16 May 2007.

References 

  1. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996;35(41):13303–13309
  2. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999;42(14):2493–2497
  3. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999;14(3):179–186
  4. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7(8):961–966
  5. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19(5):1256–1265
  6. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients–preliminary evidence of activity. J Clin Oncol. 2001;19(5):1248–1255
  7. van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs. 2002;13(4):381–393
  8. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002;8(1):75–85
  9. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7(2):231–242
  10. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480–1490
  11. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890–899
  12. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–584
  13. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23(24):5484–5492
  14. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003;98(4):832–840
  15. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38(4):543–549
  16. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18(14):2676–2684
  17. Samuels B, Rushing D, Chawla S, et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. J Clin Oncol. 2004;22:14S
  18. Gomez J, Lazaro L, Guzman C, et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol. 2000;19:187a

PII: S0936-6555(07)00646-2

doi: 10.1016/j.clon.2007.05.006

Clinical Oncology
Volume 19, Issue 8 , Pages 572-576 , October 2007

Article Tools